¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ 2022 KGOG Symposium & Workshop-1st Methodology Wroshop : 2022-08-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ 2022 KGOG Symposium & Workshop-1st Methodology Wroshop : 2022-08-20
±³À°ÀÏÀÚ : 2022-08-20
±³À°Àå¼Ò : À¯±¤»çȦ, ÃÖ´ö°æ°­ÀÇ½Ç (°í·Á´ëÇб³ÀÇ°ú´ëÇÐ)  
±³À°ÁÖÁ¦ : 2022 KGOG Symposium & Workshop-1st Methodology Wroshop
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸  
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5420  
À̸ÞÀÏ : kiskgog@hanmail.net      
±³À°Á¾·ù : »êºÎÀΰú±âŸ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 45ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-20 À¯±¤»çȦ 09:00~09:15 Overview of enrichment designs  ¼Ò°æ¾Æ(°Ç±¹´ëº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 09:15~09:30 Overview of adaptive designs  ¹é¹ÎÇö(ÇѸ²´ë¼º½Éº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 09:30~09:45 Overview of master protocols  ÀÌ»êÈñ(¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø) 
Åä·Ð 08-20 À¯±¤»çȦ 09:45~10:00 Panel Discussion  ÃÖöÈÆ, ÇÏÁ¤Àº, À̱ÙÈ£(»ï¼º¼­¿ïº´¿ø, ±¹°¡ÀÓ»ó½ÃÇèÁö¿øÀç´Ü, ¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 10:20~10:40 Gynecologic cancer clinical trials in Japan  Keiichi Fujiwara(Saitama Medical University International Medical Center) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 10:40~11:00 DSMB in phase 3 multicenter clinical trial  ·ù±Ù¿ø(±¹¸³¾Ï¼¾ÅÍÀ§¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 11:00~11:20 Road to successful clinical trials in KGOG  ÀÌÁ¤À±(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 11:20~11:40 Clinical trial of Gynecologic cancer in KROG  ¹Ú¿ø(»ï¼º¼­¿ïº´¿ø) 
Åä·Ð 08-20 À¯±¤»çȦ 11:40~11:55 Panel Discussion  ±è¹Î±Ô,¹èÀ縸,¾ö±Ù¿ë(»ï¼ºÃ¢¿øº´¿ø,ÇѾç´ëº´¿ø,ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 11:55~12:15 Pegylated Liposomal Doxorubicin(PLD) in Platinum- Sensitive Recurrent Ovarian Cancer  ÃÖÇöÁø(Á߾Ӵ뱤¸íº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 12:15~12:35 Pegylated Liposomal Doxorubicin(PLD) and bevacizumab combination for recurrent ovarian cancer  Á¤¿ë¿í(°­³²Â÷º´¿ø) 
±³À°½Ã°£ 08-20 ÃÖ´ö°æ°­ÀÇ½Ç 320È£ 11:55~12:15 Why I choose PARPi monotherapy for 1LM  Á¶ÇѺ°(°­³²¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 08-20 ÃÖ´ö°æ°­ÀÇ½Ç 320È£ 12:15~12:35 Clinical decision-making with or without HRD testing  È«¼÷Èñ(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 13:35~13:55 Study using real world data  ½É½ÂÇõ(°Ç±¹´ëº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 13:55~14:15 Study using public health data  ÃÖÈ¿±Ù(ÇѸ²´ë¼º½Éº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 14:30~14:50 6th Ovarian Cancer Consensus Conference (OCCC)  Àå¼®ÁØ(¾ÆÁִ뺴¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 14:50~15:05 Gynecologic Cancer Inter (GCIG) 2022  Á¶Çö¿õ(°í´ë±¸·Îº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 15:05~15:20 American Society of Clinical Oncology (ASCO) 2022  ³ëÁØÈ£(»ï¼º¼­¿ïº´¿ø) 
Åä·Ð 08-20 À¯±¤»çȦ 15:40~16:00 Panel Discussion  ±è»ó¿î, ³ëÀçÈ«,ÀÌ»óÈÆ(¼¼ºê¶õ½ºº´¿ø, ºÐ´ç¼­¿ï´ëº´¿ø, ¿ï»ê´ëº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 16:00~16:15 Statistics for retrospective studies and meta-analyses  ±èÇöÁ¤(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 16:15~16:30 Multi-Arm Multi-Stage (MAMS) Design in Oncologic Study  ÀÌÁ¤º¹(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 08-20 À¯±¤»çȦ 16:30~16:45 Designs for Randomized Phase II Clinical Trials  ³²º´È£(Ç층½º) 
Åä·Ð 08-20 À¯±¤»çȦ 16:45~17:00 Panel Discussion  À̼ºÁ¾,¼Û¿ëÁß,±è±âµ¿(¼­¿ï¼º¸ðº´¿ø,¾ç»êºÎ»ê´ëº´¿ø,ºÐ´ç¼­¿ï´ëº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ 2022 KGOG Symposium & Workshop-1st Methodology Wroshop : 2022-08-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦78ȸ ¿Â¶óÀÎ °³¿øÀÇ ¹× Àü°øÀÇ ¿¬¼ö°­Á : 2022-08-20
´ÙÀ½±Û ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ ºÎ»êÁöºÎÇÐȸ ÇÏ°èÇмú´ëȸ : 2022-08-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20544 ¼­¿ï 2024 Çѱ¹¸ðÀÚº¸°ÇÇÐȸ Á¦54ȸ Ãá°è¿¬¼ö°­Á : 2024-05-25 0 30 2024-04-29
20543 ¼­¿ï Çѱ¹ÀÇ·áÀ±¸®ÇÐȸ Áö¿ª»çȸ ±â¹Ý ÀÇ·á¿Í À±¸®¿ª·® °­È­ : 2024-05-25 0 36 2024-04-29
20542 °­¿ø Á¦31Â÷ ´ëÇѽŰæ¼Õ»óÇÐȸ Á¤±âÇмú´ëȸ : 2024-05-25 0 57 2024-04-29
20541 Ãæ³² Á¦4ȸ ´ëÇѺñ¸¸ÇÐȸ ÃæûÁöȸ ¿¬¼ö°­Á : 2024-05-25 0 79 2024-04-29
20540 ¼­¿ï ´ëÇѳúÀüÁõÇÐȸ ¿¬ÇÕ ½ÉÆ÷Áö¾ö : 2024-05-25 0 51 2024-04-29
20539 ¼­¿ï 2024 ÀÎÁöÁßÀçÄ¡·áÇÐȸ Ãá°è Çмú´ëȸ : 2024-05-25 0 53 2024-04-29
20538 ¼­¿ï Á¦8ȸ °­µ¿°æÈñ´ëÇб³º´¿ø ÀÓ»óÀǸ¦ À§ÇÑ ½Å°æ°ú ¿¬¼ö°­Á : 2024-05-25 0 53 2024-04-29
20537 °æºÏ 2024³âµµ °æ»óºÏµµÀÇ»çȸ Á¾ÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-25 0 56 2024-04-29
20536 ¼­¿ï (¿Â¶óÀÎ)2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦1Â÷ FLS ÄÚµð³×ÀÌÅÍ ¿öÅ©¼ó : 2024-05-24 0 66 2024-04-29
20535 Àü³² Á¦56ȸ ´ëÇѼҾƽŰæÇÐȸ Ãá°èÇмú´ëȸ day 2 : 2024-05-24 0 52 2024-04-29
20534 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-05-24 0 42 2024-04-29
20533 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ(À§¿øȸ) ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À° : 2024-05-24 0 45 2024-04-29
20532 Àü³² 2024³â ¼øõ½ÃÀÇ»çȸ Ãá°èÇмú´ëȸ(ºÎÁ¤¸Æ, ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý) : 2024-05-23 0 59 2024-04-29
20531 Àü³² Á¦56ȸ ´ëÇѼҾƽŰæÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-23 0 61 2024-04-29
20530 ¼­¿ï ¿¡ÀÌÄ¡Ç÷¯½º¾çÁöº´¿ø Á¦2024-1ȸ ¿¬¼ö°­Á : 2024-05-23 0 49 2024-04-29
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷